Evidence map›Paper›PMID 21248318›Full record

ArticleJournal of medical genetics2011

Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3.

Elena Sieni, Valentina Cetica, Alessandra Santoro, Karin Beutel, Elena Mastrodicasa, Marie Meeths, Benedetta Ciambotti, Francesca Brugnolo, Udo zur Stadt, Daniela Pende and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of medical genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01547143 (Pilot Study of First-line Immunosuppressive Therapy Combined With Etoposide and Allogeneic Hematopoietic Cell Transplantation in Refractory/Reactivated Cases for Hemophagocytic Lymphohistiocytosis), which is not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01547143 naterminatednot on this mapstarted 2012, after this paper: background citation

Pilot Study of First-line Immunosuppressive Therapy Combined With Etoposide and Allogeneic Hematopoietic Cell Transplantation in Refractory/Reactivated Cases for Hemophagocytic Lymphohistiocytosis (HLH) in Adult Patients

TypeinterventionalSponsorAsan Medical CenterRan2012 to 2016Enrolled12ConditionsHemophagocytic LymphohistiocytosisArmsIST and/or alloHCT
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. International journal of molecular sciences · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. CD8Advances in experimental medicine and biology · 2024
    Review
  12. Genetics of Primary Hemophagocytic Lymphohistiocytosis.Advances in experimental medicine and biology · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 4 countries.

Elena SieniDepartment of Pediatric Hematology and Oncology, Azienda Ospedaliero-Universitaria Meyer, Florence, Italy.
Valentina Cetica
Alessandra Santoro
Karin Beutel
Elena Mastrodicasa
Marie Meeths
Benedetta Ciambotti
Francesca Brugnolo
Udo zur Stadt
Daniela Pende
Lorenzo Moretta
Gillian M Griffiths
Jan-Inge Henter
Gritta Janka
Maurizio Aricò
Meyer Children's Hospital · ITKarolinska University Hospital · SEAddenbrooke's Hospital · GBAlleanza Contro il Cancro · ITAzienda Ospedaliera di Perugia · ITIstituto Giannina Gaslini · ITKinderkrebs-Zentrum Hamburg · DEOspedale Vincenzo Cervello · ITUniversität Hamburg · DE

Funding

Wellcome Trust 075880
6 · The paper itself

Abstract

backgroundMutations of UNC13D are causative for familial haemophagocytic lymphohistiocytosis type 3 (FHL3; OMIM 608898).

objectiveTo carry out a genotype-phenotype study of patients with FHL3.

methodsA consortium of three countries pooled data on presenting features and mutations from individual patients with biallelic UNC13D mutations in a common database.

results84 patients with FHL3 (median age 4.1 months) were reported from Florence, Italy (n=54), Hamburg, Germany (n=18), Stockholm, Sweden (n=12). Their ethnic origin was Caucasian (n=57), Turkish (n=10), Asian (n=7), Hispanic (n=4), African (n=3) (not reported (n=3)). Thrombocytopenia was present in 94%, splenomegaly in 96%, fever in 89%. The central nervous system (CNS) was involved in 49/81 (60%) patients versus 36% in patients with FHL2 (p=0.001). A combination of fever, splenomegaly, thrombocytopenia and hyperferritinaemia was present in 71%. CD107a expression, NK activity and Munc 13-4 protein expression were absent or reduced in all but one of the evaluated patients. 54 different mutations were observed, including 15 new ones: 19 missense, 14 deletions or insertions, 12 nonsense, nine splice errors. None was specific for ethnic groups. Patients with two disruptive mutations were younger than patients with two missense mutations (p<0.001), but older than comparable patients with FHL2 (p=0.001).

conclusionUNC13D mutations are scattered over the gene. Ethnic-specific mutations were not identified. CNS involvement is more common than in FHL2; in patients with FHL3 and disruptive mutations, age at diagnosis is significantly higher than in FHL2. The combination of fever, splenomegaly, thrombocytopenia and hyperferritinaemia appears to be the most easily and frequently recognised clinical pattern and their association with defective granule release assay may herald FHL3.

Indexed as

Genetic Association StudiesLymphohistiocytosis, HemophagocyticAdolescentAge of OnsetCell DegranulationChildChild, PreschoolCytotoxicity, ImmunologicFemaleGene OrderGenotypeHumansInfantInfant, NewbornKiller Cells, NaturalMaleMembrane ProteinsUNC13D protein, human

Identifiers

PMID21248318
PMCPMC4115201
OpenAlexW1980898430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.